Full Committee Hearing

“Valeant Pharmaceuticals' Business Model: the Repercussions for Patients and the Health Care System”

Date: Wednesday, April 27th, 2016

Time: 03:30pm

Location: Hart, Room 216

Panel I

Berna Heyman

Wilson Disease patient, and retired Associate Dean of Libraries

William & Mary

Download Witness Testimony
Dr. Frederick K. Askari, M.D. PhD

Associate Professor, and Director, Wilson Disease Center of Excellence

University of Michigan Health System

Download Witness Testimony
Dr. Richard Fogel M.D., FACC, FHRS

Chief Clinical Officer

St. Vincent

Download Witness Testimony

Panel II

William A. Ackman

Founder and Chief Executive Officer, Director,

Pershing Square Capitol Management LP,, Valeant Pharmaceuticals International, Inc.,

Download Witness Testimony
J. Michael Pearson

Chief Executive Officer

Valeant Pharmaceuticals International, Inc

Download Witness Testimony
Howard Schiller

Director, former Chief Financial Officer, and former Interim Chief Executive Officer

Valeant Pharmaceuticals International, Inc.,

Download Witness Testimony